nach oben

Erschienen in:

16.10.2017 | Vitiligo | gastbeitrag

Behandlungsoptionen in der Praxis

Therapie der Vitiligo

verfasst von: Prof. Dr. Michael Meurer, M. Schild

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Spektrum der Therapiemöglichkeiten bei Vitiligo hat sich in den letzten 10 Jahren deutlich erweitert, und wir können unseren Patienten, gestützt durch europäische Leitlinien und Konsensusfindung, wirksamere Behandlungsstrategien anbieten. Die topische Therapie und die UV-Therapie sind die wichtigsten Komponenten der Vitiligobehandlung, die häufig kombiniert werden. Die wichtigsten Zielparameter sind Ausmaß und Dauer der Repigmentierung, das Anhalten der Progression, Vermeidung von Nebenwirkungen und die Besserung der Lebensqualität. Die Wirksamkeit der derzeit verfügbaren Behandlungen ist oft nicht ausreichend. Neue Optionen umfassen antioxidative und melanozytenstimulierende Adjuvanstherapien meist in Kombination mit UV- oder Laserlicht sowie eine topische Erhaltungstherapie zur Rezidivprophylaxe. In vielen Fällen ist eine begleitende psychologische Betreuung sinnvoll.

Taïeb A, Picardo M, VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27–35CrossRefPubMed

Sangma LN, Nath J, Bhagabati D (2015) Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol 60:142–146CrossRefPubMedPubMedCentral

Porter JR, Beuf AH, Lerner AB, Nordlund JJ (1990) The effect of vitiligo on sexual relationships. J Am Acad Dermatol 22:221–222CrossRefPubMed

Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole C, Lee AY, Parsad D, Taïeb A, Picardo M, Ezzedine K (2015) Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res 28:363–369CrossRefPubMed

Taïeb A, Alomar A, Böhm M, Dell'Anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M (2013) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 168:5–19CrossRefPubMed

Meredith F, Abbott R (2013) Vitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K. Br J Dermatol 170:565–570CrossRef

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo. Lancet 386:74–84CrossRefPubMed

Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U (2006) Interventions for vitiligo. Cochrane Database Syst Rev 25:CD003263

Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonzélez U (2010) Interventions for vitiligo. Cochrane Database Syst Rev 20:CD003263

10.

Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, Gonzélez U, Jiyad Z, Eleftheriadou V, Ezzedine K (2015) Interventions for vitiligo. Cochrane Database Syst Rev 2:CD003263

11.

Schild M, Meurer M (2016) Vitiligo: Klinik und Pathogenese. Hautarzt 67: 173–188CrossRefPubMed

12.

Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV (2013) Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 69:e11–e18CrossRefPubMed

13.

Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 140:677–683CrossRefPubMed

14.

Taïeb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360:160–169CrossRefPubMed

15.

Hamzavi IH, Lim HW, Syed ZU (2012) Ultraviolet-based therapy for vitiligo: what's new? Indian J Dermatol Venereol Leprol 78:42–48CrossRefPubMed

16.

Van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L, Lambert J (2012) Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol 167:1017–1024CrossRefPubMed

17.

Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM (1998) Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 134:1532–1540PubMed

18.

Smith DA, Tofte SJ, Hanifin JM (2002) Repigmentation of vitiligo with topical tacrolimus. Dermatology 205:301–303CrossRefPubMed

19.

Sendur N, Karaman G, Saniç N, Savk E (2006) Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 17:338–342CrossRefPubMed

20.

Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Junger M, Bräutigam M (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205:271–277CrossRefPubMed

21.

Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, Kim JH, Song KH, Kim KH (2013) Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-a-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 27:609–616CrossRefPubMed

22.

Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498–505CrossRefPubMed

23.

Korobko IV (2012) Review of current clinical studies of vitiligo treatments. Dermatol Ther 25:17–27CrossRef

24.

Köse O, Arca E, Kurumlu Z (2010) Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat 21:133–139CrossRefPubMed

25.

Kathuria S, Khaitan BK, Ramam M, Sharma VK (2012) Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1 % tacrolimus ointment vs 0.05 % fluticasone propionate cream. Indian J Dermatol Venereol Leprol 78:68–73CrossRefPubMed

26.

Aschoff R, Schwanebeck U, Bräutigam M, Meurer M (2009) Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1 % in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 18:24–29CrossRefPubMed

27.

Czarnecka-Operacz M, Jenerowicz D (2012) Topical calcineurin inhibitors in the treatment of atopic dermatitis — an update on safety issues. J Dtsch Dermatol Ges 10:167–172PubMed

28.

Wazir SM, Paracha MM, Khan SU (2010) Efficacy and safety of topical mometasone furoate 0.01 % vs. tacrolimus 0.03 % and mometasone furoate 0.01 % in vitiligo. J Pak Assoc Dermatol 20:89–92

29.

Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group (2004) Long-term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology 208:365–372

30.

Yones SS, Palmer RA, Garibaldinos TM, Hawk JL (2007) Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen- UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 143:578–584CrossRefPubMed

31.

Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T (2015) Maintenance therapy of adult vitiligo with 0.1 % tacrolimus ointment: a randomized, double blind, placebocontrolled study. J Invest Dermatol 135:970–974CrossRefPubMed

32.

Kapoor R, Phiske MM, Jerajani HR (2009) Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 160:861–863CrossRefPubMed

33.

Hossani-Madani AR, Halder RM (2010) Topical treatment and combination approaches for vitiligo: new insights, new developments. G Ital Dermatol Venereol 145:57–78PubMed

34.

Birlea SA, Costin GE, Norris DA (2008) Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 9:345–359CrossRefPubMed

35.

Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10:153–163CrossRefPubMed

36.

Picardo M (2010) In: Picardo M, Taïeb A (Hrsg) Vitiligo. Springer-Verlag, Berlin, S 339–342CrossRef

37.

Chiavérini C, Passeron T, Ortonne JP (2002) Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 16:137–138CrossRefPubMed

38.

Kumaran MS, Kaur I, Kumar B (2006) Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad

39.

Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, Hibberts NA (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVBactivated pseudocatalase. J Investig Dermatol Symp Proc 4:91–96CrossRefPubMed

40.

Gibbons NC, Wood JM, Rokos H, Schallreuter KU (2006) Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol 126:2576–2582CrossRefPubMed

41.

Schallreuter KU, Wood JM, Lemke KR, Levenig C (1995) Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 190:223–229CrossRefPubMed

42.

Schallreuter KU, Salem MM (2010) Vitiligo. What is new? Hautarzt 61:578–585CrossRefPubMed

43.

Bakis-Petsoglou S, Le Guay JL, Wittal R (2009) A randomized, doubleblinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 161:910–917CrossRefPubMed

44.

Naini FF, Shooshtari AV, Ebrahimi B, Molaei R (2012) The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot study. J Res Pharm Pract 1:77–80CrossRefPubMedPubMedCentral

45.

Galarza C, Ramos W, Gutierrez EL, Oré R, Chía H, évila J, Tello M, Ronceros G, Uribe M, Gémez D, Ortega-Loayza AG (2009) Efficacy and security of topical antioxidant therapy versus placebo in the treatment of vitiligo of recent onset. Dermatología Peruana 19:198–204

46.

Schallreuter KU (2013) Q10-triggered facial vitiligo. Br J Dermatol 169:1333–1336CrossRefPubMed

47.

Wu CS, Lan CC, Wang LF, Chen GS, Wu CS, Yu HS (2007) Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 156:122–129CrossRefPubMed

48.

Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA (2015) Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol 135:2068–2076CrossRefPubMedPubMedCentral

49.

Jamal S, Schneider RJ (2002) UVinduction of keratinocyte endothelin- 1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest 110:443–452CrossRefPubMedPubMedCentral

50.

Wu CS, Yu CL, Wu CS, Lan CC, Yu HS (2004) Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 13:755–763CrossRefPubMed

51.

Karsli N, Akcali C, Ozgoztasi O, Kirtak N, Inaloz S (2014) Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 42:799–805CrossRefPubMed

52.

Rana S, Rogers LJ, Halliday GM (2011) Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 178:2783–2791CrossRefPubMedPubMedCentral

53.

Park KK, Liao W, Murase JE (2012) A review of monochromatic excimer light in vitiligo. Br J Dermatol 167:468–478CrossRefPubMed

54.

Sun Y, Wu Y, Xiao B, Li L, Li L, Chen HD, Gao XH (2015) Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat 26:347–353CrossRefPubMed

55.

Bansal S, Sahoo B, Garg V (2013) Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed 29:311–317CrossRefPubMed

56.

Dell'Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, Leone G, Calzavara PG, Westerhof W, Picardo M (2007) Antioxidants and narrow band-UVB in the treatment of vitiligo: a doubleblind placebo controlled trial. Clin Exp Dermatol 32:631–636CrossRefPubMed

57.

Lu L, Wang S, Fu L, Liu D, Zhu Y, Xu A (2015) Bilobalide protection of normal human melanocytes from hydrogen peroxide-induced oxidative damage via promotion of antioxidase expression and inhibition of endoplasmic reticulum stress. Clin Exp Dermatol. [Epub ahead of print] PMID: 26178968

58.

Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 28:285–287CrossRefPubMed

59.

Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW (2013) The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 149:68–73CrossRefPubMed

60.

Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M (2015) Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151:42–50CrossRefPubMed

61.

Rath N, Kar HK, Sabhnani S (2008) An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 74:357–360CrossRefPubMed

62.

Speeckaert R, Speeckaert MM, van Geel N (2015) Why treatments do(n't) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev 14:332–340CrossRefPubMed

63.

Gokhale BB (1979) Cyclophosphamide and vitiligo. Int J Dermatol 18:92PubMed

64.

Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ (1990) Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 126:339–350CrossRefPubMed

65.

Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17:151–153CrossRefPubMed

66.

Singh H, Kumaran MS, Bains A, Parsad D (2015) A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology 231:286–290CrossRefPubMed

67.

Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D (2007) Etanercept in the treatment of vitiligo. Dermatology 215:84–85CrossRefPubMed

68.

Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC (2015) Tumour necrosis factor-a inhibition can stabilize disease in progressive vitiligo. Br J Dermatol 173:641–650CrossRefPubMedPubMedCentral

69.

Ruiz-Argüelles A, García-Carrasco M, Jimenez-Brito G, Sénchez-Sosa S, Pérez-Romano B, Garcés-Eisele J, Camacho-Alarcón C, Reyes-Núñez V, Sandoval-Cruz M, Mendoza-Pinto C, López-Colombo A (2013) Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 174:229–236PubMedPubMedCentral

70.

Craiglow BG, King BA (2015) Tofacitinib Citrate for the Treatment of Vitiligo: a Pathogenesis-Directed Therapy. JAMA Dermatol 151:1110–1112CrossRefPubMed

71.

Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988–2990CrossRefPubMed

72.

Lee DY, Choi SC, Lee DY (2012) A proposal for the treatment guideline in segmental vitiligo. Int J Dermatol 51:1274–1275CrossRefPubMed

73.

Parsad D, Gupta S, IADVL Dermatosurgery Task Force (2008) Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol 74:37–45

74.

Malakar S, Dhar S (1999) Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. Dermatology 198:133–139CrossRefPubMed

75.

Das SS, Pasricha JS (1992) Punch grafting as a treatment of residual lesions of vitiligo. Indian J Dermatol Venereol Leprol 58:315–319

76.

Kovacs D, Abdel-Raouf H, Al-Khayyat M, Abdel-Azeem E, Hanna MR, Cota C, Picardo M, Anbar TS (2015) Vitiligo: characterization of melanocytes in repigmented skin after punch grafting. J Eur Acad Dermatol Venereol 29:581–590CrossRefPubMed

77.

Wassef C, Lombardi A, Khokher S, Rao BK (2013) Vitiligo surgical, laser, and alternative therapies: a review and case series. J Drugs Dermatol 12:685–691PubMed

78.

Babu A, Thappa DM, Jaisankar TJ (2008) Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo. Dermatol Surg 34:166–178CrossRefPubMed

79.

Olsson MJ, Juhlin L (2002) Longterm follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 147:893–904CrossRefPubMed

80.

Mulekar SV, Isedeh P (2013) Surgical interventions for vitiligo: an evidence-based review. Br J Dermatol 169(Suppl 3):57–66CrossRefPubMed

81.

Falabella R (2009) Vitiligo and the melanocyte reservoir. Indian J Dermatol 54:313–318CrossRefPubMedPubMedCentral

82.

Sacchidanand S, Thakur P, Purohit V, Sujaya SN (2013) Follicular unit extraction as a therapeutic option for vitiligo. J Cutan Aesthet Surg 6:229–231CrossRefPubMedPubMedCentral

83.

Dhar S, Banerjee R, Malakar R (2014) Vitiligo in Children. In: Lahiri K, Chatterjee M, Sarkar R (Hrsg) Pigmentary disorders: a comprehensive compendium. Jaypee Brothers Medical Publishers(P) Ltd, New Delhi, S 167–179

84.

Rao J, Fitzpatrick RE (2004) Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 30:1043–1045PubMed

85.

Alghamdi KM, Kumar A (2011) Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 25:749–757CrossRefPubMed

86.

Radmanesh M (2000) Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy. J Eur Acad Dermatol Venereol 14:149–152CrossRefPubMed

87.

Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor J, Corne J, Lamb B, Ersser S, Ravenscroft J, Thomas KS (2011) Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol 164:530–536PubMedPubMedCentral

88.

Papadopoulos L, Bor R, Legg C (1999) Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 72:385–396CrossRefPubMed

89.

Boone B (2007) Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 17:55PubMed

Titel: Behandlungsoptionen in der Praxis
Therapie der Vitiligo
verfasst von: Prof. Dr. Michael Meurer
M. Schild
Publikationsdatum: 16.10.2017
Verlag: Springer Medizin
Schlagwörter: Vitiligo
Tacrolimus
Erschienen in: ästhetische dermatologie & kosmetologie / Ausgabe 5/2017
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI: https://doi.org/10.1007/s12634-017-5517-9

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Therapie der Vitiligo

Zusammenfassung

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Augen-Make-up schonend und wirkungsvoll entfernen

Ärzte wollen bei Digital Healthcare Taktgeber werden

„Was nach einem halben Jahr noch da ist, das bleibt“

Salbe erhält Status als Medizinprodukt

PDT-Pflaster zur Behandlung von aktinischen Keratosen

Pflege für trockene Füße

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie